CVM

CEL-SCI Corporation (CEL-SCI) - 10-K Summary

Business Context and Reporting Period

Period: Fiscal year ended September 30, 2008.
Business: CEL-SCI is a biotechnology company developing Multikine, an immunotherapy drug for cancer treatment. The lead indication is advanced primary head and neck cancer. The company has received FDA clearance for a global Phase III clinical trial but requires additional funding to launch it. CEL-SCI also holds pre-clinical technology (L.E.A.P.S.) for vaccines targeting herpes, malaria, and rheumatoid arthritis.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Crisis: Cash and cash equivalents plummeted by approximately $10.3 million, dropping from $11.0 million to $0.7 million. Working capital turned negative, moving from a surplus of $10.3 million to a deficit of $2.5 million.
• Operating Expenses: R&D expenses increased by $1.57 million (62%) due to preparations for the Phase III trial. Conversely, G&A expenses decreased by $1.5 million, primarily due to a reduction in stock-based compensation for consultants compared to the prior year.
• Revenue: Grant revenue declined significantly as previous grants expired, leaving only minimal training grants and sublet rent income.
• Derivative Gains: The company recognized a $1.8 million gain on derivative instruments (Series K Notes and Warrants) due to fluctuations in stock price, partially offsetting the net loss.
• Capital Expenditures: Significant cash was used ($2.36 million) to complete the new manufacturing facility in Maryland, which was taken into possession in October 2008.

Outlook, Risks, and Contingencies

• Going Concern: The independent auditor has issued an opinion expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and negative working capital.
• Financing Needs: The company must raise additional capital to launch the Phase III trial. It is pursuing partnerships, joint ventures, and a $5 million Equity Line of Credit (established Dec 2008) to fund operations through January 2010.
• Debt Obligations: Holders of Series K convertible notes may require repayment of the entire principal balance ($2.24 million) at any time after August 4, 2009. The debt can be settled in stock or cash.
• Lease Default Risk: In December 2008, the company failed to pay an installment of base annual rent for its manufacturing facility. While not formally declared in default, the landlord has the right to do so if payments are not made within 5 business days of notice. The company is negotiating rent deferrals.
• Subsequent Events: In November 2008, a licensing agreement with Orient Europharma was extended, securing a $500,000 investment. Two senior executives transitioned to consultant roles in December 2008 to reduce costs.

Investor Verification Checklist

• Cash Runway: Verify the status of the $5 million Equity Line of Credit and whether drawdowns have been utilized to cover the rent default and operating losses.
• Debt Settlement: Confirm if the Series K debt holders have exercised their put option or if a settlement plan (cash vs. stock) has been finalized for the August 2009 deadline.
• Lease Status: Determine if the rent deferral agreement with the manufacturing facility landlord was successfully executed to avoid formal default.
• Phase III Funding: Assess the progress of partnership negotiations to fund the global Phase III clinical trial, which is critical for the company's future revenue potential.
• Stock Dilution: Monitor the impact of potential debt conversion and equity line drawdowns on existing shareholder dilution.